NCT03236428 2026-03-27
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
19 trialsNCT04850846 2026-02-09
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT04920084 2025-09-09
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT03951220 2025-08-19
LOOMIS
Oxford University Hospitals NHS Trust
Completed
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00112827 2025-06-06
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT02903381 2023-06-13
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02279394 2023-06-09
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02943473 2020-12-16
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT02492750 2020-03-25
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT01884688 2017-04-17
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT00983346 2016-07-11
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
Phase 2 Terminated
NCT00942422 2015-03-27
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02353572 2015-03-09
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
University of Colorado, Denver
Phase 1/2 Terminated
NCT01302366 2015-02-12
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
NYU Langone Health
Phase 2 Terminated
NCT00899353 2013-12-12
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Marshall University
Phase 2 Terminated